Abstract
This paper explores price differences in the European Union (EU) pharmaceutical market, the EU’s
fifth largest industry. With the aim of enhancing quality of life along with industry competitiveness
and R&D capability, many EU directives have been adopted to achieve a single EU-wide pharmaceutical
market. Using annual 1994–2003 data on prices of molecules that treat cardiovascular disease, we
examine whether drug price dispersion has indeed decreased across five EU countries. Hedonic regressions
show that over time, cross-country price differences between Germany and three of the four other
EU sample countries, France, Italy and Spain, have declined, with relative prices in all three as well
as the fourth country, UK, rising during the period. We interpret this as evidence that the EU has come
closer to achieving a single pharmaceutical market in response to increasing European Commission
coordination efforts.